Helix BioMedix Inc

OTC:HXBM

Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is focused on drug development for treatment of rare dermatological diseases. The firm's research and development (R&D) consists of a proprietary library of patented bioactive peptides based on the body’s innate immunity. The firm is focused on developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum (XP). HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on cellular repair pathways. HB4208 is in the preclinical development Phase. The firm is also engaged in identifying the precise peptides needed to stimulate cellular processes and control cell wall defense. Using the specific amino acid sequence for the desired activity, the Company's peptides work with targeted precision to provide optimal skin enhancing results in cosmeceutical and over the counter (OTC) formulations. Its peptides include Oligopeptide-10, Palmitoyl Hexapeptide-14 and others.